Judith Lin, MD
Rheumatology · Hilliard, OHNPI 1356769723
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,796 of the $2,147 with a category attached, or 83.7%. Roche Products Limited accounts for 94.8% of it on its own, with 2 other manufacturers making up the rest.
Across 5 payments — averaging $429.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Products Limited$2K
- Aurinia Pharma U.S., Inc.$76
- Novartis$35
Across 27 payments — averaging $9541.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$177K
- GSK$46K
- Pfizer$26K
- AbbVie$8K
- E.r. Squibb & Sons, L.L.C.$15
What the payments were for
- Travel & lodging$1,79684%
- Food & beverage$35116%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Products Limited | 3 | $2,036 |
| Aurinia Pharma U.S., Inc. | 1 | $76 |
| Novartis | 1 | $35 |
How this compares
$2,147 in reported general payments places this provider in the 55th percentile of 255 rheumatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 27 | $259,624 |
| BenlystaBelimumab | 20 | $84,179 |
| RinvoqUpadacitinib | 14 | $74,665 |
| Actemra ActpenTocilizumab | 13 | $63,778 |
| OtezlaApremilast | 12 | $52,105 |
| Hydroxychloroquine Sulfate | 345 | $14,458 |
| Mycophenolate Mofetil | 61 | $11,886 |
| Leflunomide | 75 | $4,574 |
| Colchicine | 51 | $3,033 |
| Tacrolimus | 22 | $2,855 |
| Azathioprine | 53 | $2,482 |
| MethotrexateMethotrexate Sodium | 111 | $2,420 |
| Sulfasalazine | 39 | $980 |
| Pilocarpine Hcl | 14 | $887 |
| Prednisone | 138 | $862 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Hilliard
- Leonard CalabreseCleveland$1.9M
- Gregory DelorenzoCincinnati$1.3M
- Alexa MearaColumbus$426K
- Chad DealCleveland$375K
- David MandelMayfield Village$352K
- Muhammad KhanCleveland$262K
- Chacko AlappattMiamisburg$258K
- Adam BrownCleveland$247K
- Nikita HegdeStow$198K
- M Elaine HusniCleveland$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.